Division of Neurology, Lahey Hospital & Medical Center, Burlington, MA, United States of America; Tufts University School of Medicine, Boston, MA, United States of America.
Division of Neurology, Lahey Hospital & Medical Center, Burlington, MA, United States of America; Tufts University School of Medicine, Boston, MA, United States of America.
J Neuroimmunol. 2020 Apr 15;341:577184. doi: 10.1016/j.jneuroim.2020.577184. Epub 2020 Feb 3.
We present an illustrative case of a 62-year-old woman with small cell lung cancer who developed progressive worsening of pre-existing anti-Hu antibody associated sensory neuronopathy after treatment with programmed cell death-1 (PD-1) inhibitor, nivolumab. We review the literature and identify 6 reported cases to understand the clinical outcomes of patients with anti-Hu paraneoplastic neurologic syndrome (PNS) treated with anti-PD-1 treatment. The PNS clinical spectrum comprised of encephalitis, a combination of sensory neuronopathy and anti-NMDAR encephalitis, isolated sensory neuronopathy, and encephalomyelitis. Immune checkpoint inhibitor have the potential to worsen pre-existing anti-Hu PNS and may promote the development of anti-Hu PNS.
我们呈现了一例具有说明性的病例，一名 62 岁女性患有小细胞肺癌，在接受程序性细胞死亡-1（PD-1）抑制剂纳武利尤单抗治疗后，先前存在的抗 Hu 抗体相关感觉神经元病逐渐恶化。我们回顾了文献，并确定了 6 例已报道的病例，以了解抗 PD-1 治疗后抗 Hu 副肿瘤神经综合征（PNS）患者的临床结局。PNS 的临床谱包括脑炎、感觉神经元病和抗 NMDAR 脑炎的组合、孤立性感觉神经元病和脑脊髓炎。免疫检查点抑制剂有可能使先前存在的抗 Hu PNS 恶化，并可能促进抗 Hu PNS 的发展。
